

## GLOBAL TRAINING PROGRAMME

## FORM 1 APPLICATION FORM: GLOBAL TRAINING PROGRAMME **REFERENCIA: EHU34**

CORPORATIVE INFORMATION							
Name of the company			Scantox Neuro GmbH				
Contact Person			Dr. Stefanie	e Flunk	kert	Email:	
Country			Autria				
Location	City	City		Grambach			
	Address		Parkring 12	2, 8074	4 Grambach		
Sector			Neurophar	Neuropharmacology			
		<u>PF</u>	ROPOSED INT	TERNH	ISP INFORMATION		
Number of trainees than 1 trainee, indi where they will wo	cate the differ		3 (In vivo, Histology, In vitro)				
Extension time (extra months and salary) OPTIONAL		Extra months	6				
<u>SEE DOCUMENT:</u> <i>"FORM 2_Global Training 2023</i> <i>extension preliminary</i> <i>agreement"</i>		Monthly payment for extra months (between 0- 1600€/month)	€1.600,-				
INTERNSHIP/PLACEMENT INFORMATION							
Department			1. In vivo 2. Histology 3. In vitro				
Description of project/activities			1. C c v t c c 2. C c a f 3. C c c c c c c c c c c c c v v t t c c v v t t c c v v t t c c v v t t c c v v t t c c c v v t t c c c v t t c c c c	<ul> <li>diseases, e. g. Alzheimer's or Parkinson's disease, including validation or establishment of behavioral tests, performance of behavioral tests relating to motor, cognition, activity, or anxiety deficits. Tissue sampling.</li> <li>2. Characterization of the neuropathology of a new rodent model for neurodegenerative diseases, e. g. Alzheimer's or Parkinson's disease, including sectioning of brain tissue, immunohistochemical and/or immunofluorescent labelling of rodent brain tissue, fluorescence microscopy, image analysis</li> </ul>			
	COMPETENCES, SKILLS and EXPERIENCE REQUIREMENTS						
<b>Requested profile(s) information</b> (Studies, previous experience, language skills, other skills)			St	tudies	Internship 1: First expo obligatory (e.g. housin tests of mice or rats)		in in vivo rodent work ling, treatment or behavioural









## UNIVERSITY OF THE BASQUE COUNTRY

		Internship 2: First experiences in histological methods or neurodegenerative disease research Internship 3: First experiences in molecular biological / biochemical methods First experiences in cell culture experiments are an advantage
	Language skills	Good English or German skills (one of the two is obligatory)
	<b>Other</b> (professional experience, software, other skills)	Able to work in a team
Other commentaries	none	

Director Neuropharmacology       I       Signer Name: Manuela Prokesch         Signing Reason: I approve this document	COMPANY/INSTITUTION	SIGNATURE	DATE	
	Dr. Manuela Prokesch	Manula Prokesch     Signer Name: Manuela Prokesch	May 13, 2024   C	9:00

DBAB09A0517848E1BF28CB66A2347FE1









## **INFORMATION ABOUT THE COMPANY/INSTITUTION**

LOGO	scantox
WEBSITE	www.scantox.com https://scantox.com/services/discovery/
INFORMATION ABOUT THE CITY AND THE AREA WHERE THE COMPANY/ISTITUTION IS LOCATED (General information about SECURITY, ACCOMODATION, PUBLIC TRANSPORT)	The company is located in Grambach, just south of Graz, Styria, Austria, close to the Slovenian border. From Graz, the company can be reached by bus. The airport Thalerhof of Graz is just outside the city and can be reached by public transportation. Graz was cultural capital of Europe in 2003 and offers many touristic destinations. The city is the second largest of Austria with several Universities. Graz is a very safe city. The city is surrounded by woods and mountains, so hiking, mountain biking, skiing etc. can be done close by. Many of these locations can also be reached by bus or train. Support finding appropriate accommodation can be provided.
GENERAL INFORMATION ABOUT THE COMPANY/INSTITUTION	Scantox Neuro (previously known as QPS Austria) is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, rare diseases, lysosomal storage diseases and mental disorders. Validated transgenic and non-transgenic in vitro and in vivo models covering targets of Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases are available and used to test new drugs against neuronal diseases.
SIZE OF THE COMPANY (EMPLOYEES)	Appr. 100 employees in Austria
NUMBER OF PEOPLE AT THE DEPARTMENT WHERE THE TRAINEESHIP WILL TAKE PLAKE	In vivo research: appr. 10 employees (internship 1) Histology: appr. 8 employees (internship 2) In vitro: appr. 15 employees (Internship 3)
MAIN ACTIVITY OF THE COMPANY/INSTITUTION	Contract research in the field of neurodegenerative diseases as well as clinical research in all indications.
A BRIEF EXPLANATION OF MAIN PROJECTS	Internship 1-3: Interns will all support the in-house R&D efforts. They will develop and characterize new in vitro and animal models of different diseases like Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis, Huntington's disease, Gaucher disease, Niemann Pick disease etc Animal models are characterized for behavioral deficits and afterwards, (brain) tissue is analyzed using biochemical and histological methods. New methods for characterization are developed and established. For contract research, developed and characterized models are used to test new compounds against the corresponding disease. The effect of a compound is tested using the same methods as described for the characterization.









PREVIOUS COLLABORATION IN INTERNSHIP/TRAINING PROGRAMMES?	<ul> <li>Global training program: 1 intern started in 2014, 1 intern in 2015, 2 interns in 2016, 3 interns in 2017, 3 interns in 2018, 3 interns in 2019; no intern in 2020 due to COVID, 3 interns in 2021; 2 interns in 2022, 3 intern in 2023. Several of them received either a permanent working contract or started their PhD thesis at Scantox Neuro after completion of the programme.</li> <li>Additional interns by ERASMUS</li> <li>Constantly Bachelor, Master and PhD students performing their thesis at Scantox Neuro, currently 3 PhD students</li> </ul>
OTHER COMMENTARIES	None





